InsiderTrades

Form 4 for TYRA Tyra Biosciences, Inc.

Accepted 2023-03-31 00:00:00 ET · period of report 2023-03-29 · accession 0001209191-23-021947 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-03-31 2023-03-29+ TYRA Harris Todd CEO, Dir M - OptEx $2.25 +4,327 1.70M +0.3% +$9,736
DM 2023-03-31 2023-03-29+ TYRA Harris Todd CEO, Dir S - Sale+OE $16.08 -4,327 1.70M -0.3% -$69.6K
DM 2023-03-31 2023-03-29+ TYRA Harris Todd CEO, Dir M - OptEx $0.00 -4,327 400.0K -1% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-03-30 M A 2,407 $2.25 1,703,683 D — —
2 Common Common Stock 2023-03-31 S D 500 $16.05 1,701,276 D — —
3 Common Common Stock 2023-03-29 S D 1,420 $16.18 1,701,276 D — —
4 Common Common Stock 2023-03-30 S D 2,407 $16.02 1,701,276 D — —
5 Common Common Stock 2023-03-31 M A 500 $2.25 1,701,776 D — —
6 Common Common Stock 2023-03-29 M A 1,420 $2.25 1,702,696 D — —
7 Derivative Stock Option (Right to Buy) 2023-03-31 M D 500 $0.00 399,537 D $2.25 · — to 2031-03-09 500 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.
8 Derivative Stock Option (Right to Buy) 2023-03-29 M D 1,420 $0.00 402,444 D $2.25 · — to 2031-03-09 1,420 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.
9 Derivative Stock Option (Right to Buy) 2023-03-30 M D 2,407 $0.00 400,037 D $2.25 · — to 2031-03-09 2,407 Common Stock (F2) 1/48th of the shares subject to the option vest monthly following March 5, 2021, the vesting commencement date.